a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
Published 5 months ago • 72 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
2:25
results from a phase i/ii trial of pirtobrutinib and lv20.19 for patients with r/r lymphomas
-
1:18
results of a phase i study of sonrotoclax for the treatment of r/r waldenström’s macroglobulinemia
-
1:12
cpx-351 with venetoclax in r/r aml: results of a phase ib study
-
2:32
the current soc for patients with primary cns lymphoma
-
1:46
phase ii trial in progress: astx727 ± venetoclax in newly diagnosed mds/mpn
-
1:06
epcore nhl-1: two and a half year follow-up of epcoritamab in dlbcl
-
12:49
3mensio ct pre-case planning: valve-in-valve tavr in homograft
-
11:11
3mensio ct pre-case planning: tavr with high coronary obstruction risk
-
8:26
immunohistochemistry and cytogenetics for non hodgkins lymphoma
-
1:56
overview of the clinical management of patients with myelofibrosis
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
3:07
ibrutinib venetoclax in treatment-naïve wm: results from a phase ii trial
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
1:37
a phase ii trial evaluating e7820 in patients with aml with splicing factor mutations
-
2:43
venetoclax and intensive chemotherapy in npm1-mutated aml: findings from the caveat study
-
4:21
hovon 141/vision trial update: mrd-guided venetoclax ibrutinib treatment for r/r cll
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
1:11
distinkt trial analysis: efficacy and safety of imc-001 for r/r enktl
-
2:15
updates from the phase ii aern trial: nivolumab and radiotherapy for the treatment of r/r hl
-
1:01
clinical outcomes for patients with myelofibrosis after transition from ruxolitinib to momelotinib